Recent news on Nph Insulin

Hypoglycemia: Answering the Challenge With Long-acting Insulin Analogs  -  May 18, 2007
Medscape (subscription)Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes.

Intensive Glucose Control in Elderly Adults—Reply  -  May 22, 2007
Journal of American Medical Association (subscription),The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care.

New Data Confirm That Use Of Levemir® Can Limit Weight Gain  -  Apr 23, 2007
Medical News Today (press release),Compared to conventional long-acting insulins such as NPH insulin, Levemir® causes less fluctuation in blood glucose levels across the day and has greater

Traditional Insulin Compares Well Against Analogs  -  Apr 18, 2007
MedPage Today,GRAZ, Austria, April 18 -- Newer long-acting insulin analogs are only marginally better at preventing nighttime hypoglycemia than traditional NPH insulin,

New, Old Insulin Drugs Equally Good  -  Apr 18, 2007
WebMDThe reviewers found that NPH insulin and the long-acting insulin treatments yielded similar blood sugar (glucose) control in the studies.

Insulin Analogs or Premixed Insulin Analogs in Combination With ...  -  Apr 17, 2007
Medscape (subscription)Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic

New Data Confirm That Use of Levemir Can Limit Weight Gain  -  Apr 3, 2007
PipelineReview.com (press release),...insulin initiation in type 2 diabetes, mean weight gain was reduced by more than 50% when comparing Levemir(R) to equivalent regimens of NPH insulin.

Levemir® Approved In Europe For Use In Combination With Oral ...  -  Mar 12, 2007
Medical News Today (press release),Levemir® initiated once daily significantly improves blood glucose levels, with less weight gain compared to NPH insulin and insulin glargine.

Generex Biotechnology Announces New Oral Insulin Clinical Data  -  Nov 28, 2006
PharmaLive.com (press release),NEW YORK, November 28, 2006 -Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining

Generex Biotechnology Announces New Oral Insulin Clinical Data  -  Nov 28, 2006
Market Wire (press release)TORONTO -- (MARKET WIRE) -- November 28, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases

New Data from the Predictive Study Shows That Levemir (insulin ...  -  Dec 5, 2006
PharmaLive.com (press release),The time-action profile of Levemir® is less variable and therefore more predictable than for NPH insulin.(4) Levemir® can be used once daily and has a

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional